Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 29 (1) , 77-85
Abstract
Objective Hormonal management is an alternative treatment for preserving fertility in patients with presumed early stage endometrioid endometrial cancer. This study aimed to define the pregnancy and oncologic outcomes and factors of successful conception after hormone therapy for endometrioid endometrial cancer. Methods We retrospectively analyzed patients presumed to have stage IA, grade 1–2 endometrioid endometrial cancer who underwent fertility-sparing treatment. Concurrent medroxyprogesterone and levonorgestrel-release intra-uterine devices were used for treatment. The pregnancy outcomes and oncologic outcomes were compared between the pregnant and non-pregnant groups. Results Seventy-one patients presumed to have stage IA, grade 1–2 endometrioid endometrial cancer had complete remission, and 49 of them tried to conceive. Twenty-two (44.9%) patients became pregnant; the total number of pregnancies was 30. These pregnancies resulted in seven abortions (23.3%), one pre-term birth (3.3%), and 20 full-term births (66.6%). The total live birth rate was 66.6 % (20/30). The median duration of hormonal treatment was 11.9 months (range 4–49) and 12.0 months (range 3–35) in the pregnant and non-pregnant groups, respectively. On multivariate analysis, age, body mass index, treatment duration, medroxyprogesterone dose, and number of dilatation and curettage biopsies were not significantly associated with pregnancy failure, but the association with grade (OR 6.2, 95% CI 1.0 to 38.9; PConclusions A lower grade might be a positive factor for future pregnancy. Moreover, successful pregnancy might be a factor in preventing recurrence.Keywords
This publication has 41 references indexed in Scilit:
- Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010Journal of Gynecologic Oncology, 2013
- Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic reviewGynecologic Oncology, 2012
- Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literatureGynecologic Oncology, 2012
- Fertility-Sparing Therapy in Young Women With Endometrial CancerInternational Journal of Gynecological Cancer, 2010
- Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinomaAmerican Journal of Obstetrics and Gynecology, 2009
- Fertility-Sparing in Endometrial CancerGynecologic and Obstetric Investigation, 2009
- Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young WomenJournal of Clinical Oncology, 2007
- Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United StatesGynecologic Oncology, 2005
- Tumor-Associated Proteolytic Factors uPA and PAI-1 in Endometrial CarcinomaGynecologic Oncology, 1997
- Progestin alone as primary treatment of endometrial carcinoma in premenopausal womenCancer, 1997